Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) SVP Heidi L. Wagner sold 120 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $122.41, for a total value of $14,689.20. Following the completion of the transaction, the senior vice president now directly owns 31,995 shares of the company’s stock, valued at approximately $3,916,507.95. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 125.51 on Thursday. Alexion Pharmaceuticals Inc. has a 12-month low of $110.56 and a 12-month high of $193.45. The company’s 50-day moving average price is $128.24 and its 200 day moving average price is $134.99. The stock has a market cap of $28.15 billion, a price-to-earnings ratio of 315.35 and a beta of 1.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the consensus estimate of $1.17 by $0.04. The company had revenue of $753 million for the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The firm’s revenue was up 18.4% on a year-over-year basis. During the same period last year, the business earned $1.44 earnings per share. On average, equities analysts predict that Alexion Pharmaceuticals Inc. will post $4.67 earnings per share for the current year.

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

A number of hedge funds have recently bought and sold shares of the company. Glenmede Trust Co. NA raised its stake in shares of Alexion Pharmaceuticals by 38.1% in the first quarter. Glenmede Trust Co. NA now owns 3,077 shares of the biopharmaceutical company’s stock valued at $427,000 after buying an additional 849 shares during the last quarter. Virginia Retirement System acquired a new stake in shares of Alexion Pharmaceuticals during the first quarter valued at approximately $509,000. Prudential Financial Inc. raised its stake in shares of Alexion Pharmaceuticals by 2.8% in the first quarter. Prudential Financial Inc. now owns 345,718 shares of the biopharmaceutical company’s stock valued at $48,131,000 after buying an additional 9,460 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Alexion Pharmaceuticals by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 5,601,869 shares of the biopharmaceutical company’s stock valued at $779,892,000 after buying an additional 15,733 shares during the last quarter. Finally, Columbia Partners L L C Investment Management raised its stake in shares of Alexion Pharmaceuticals by 0.3% in the first quarter. Columbia Partners L L C Investment Management now owns 41,709 shares of the biopharmaceutical company’s stock valued at $5,806,000 after buying an additional 116 shares during the last quarter. 96.34% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently issued reports on the company. Leerink Swann reaffirmed a “buy” rating and issued a $200.00 price target on shares of Alexion Pharmaceuticals in a research report on Sunday, July 17th. Credit Suisse Group AG upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Saturday, July 9th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Sunday, June 26th. Cowen and Company reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 29th. Finally, Vetr downgraded Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price objective for the company. in a report on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $178.32.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.